Additional information:
PI-273 is a first reversibly and specific phosphatidylinositol 4-kinase (PI4KIIα) inhibitor with an IC50 of 0.47 μM. PI-273 can inhibit breast cancer cell proliferation, block the cell cycle and induce cell apoptosis.|Product information|CAS Number: 925069-34-7|Molecular Weight: 381.90|Formula: C16H16ClN3O2S2|Chemical Name: 2-({[(4-chlorophenyl)formamido]methanethioyl}amino)-4-ethyl-5-methylthiophene-3-carboxamide|Smiles: CC1SC(NC(=S)NC(=O)C2C=CC(Cl)=CC=2)=C(C=1CC)C(N)=O|InChiKey: MIERMBQDBLFAFW-UHFFFAOYSA-N|InChi: InChI=1S/C16H16ClN3O2S2/c1-3-11-8(2)24-15(12(11)13(18)21)20-16(23)19-14(22)9-4-6-10(17)7-5-9/h4-7H,3H2,1-2H3,(H2,18,21)(H2,19,20,22,23)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 6.PMID:32538180 02 mg/mL (15.76 mM; ultrasonic and warming and heat to 60°C)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥360 days if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|PI-273 (2 μM; 48 hours) blocks the cell cycle at the G2-M phase. PI-273 (2 μM; 48 hours) induces cell apoptosis in all three Ras wild-type breast cancer cells: MCF-7, T-47D, and SK-BR-3. PI-273 (0.5-2 μM; for 3 days) can suppress the AKT signaling pathway in a dose- and time-dependent manner. PI-273 of 1 μM and 2 μM inhibits the cell proliferation of both MCF-7 and T-47D cells in a time-dependent manner.|In Vivo:|PI-273 (intraperitoneal injection; 25 mg/kg/day; 15 days) profoundly suppresses the tumor volume and weight in the MCF-7 xenografts. PI-273 (0.5 mg/kg (intravenously) or 1.5 mg/kg (intragastrically); 0.08-5 hours) has a half-life of 0.411 hours for intravenous administration and 1.321 hours for intragastrical administration, and the absolute bioavailability of PI-273 is 5.1%.|References:|Li J, et al. PI-273, a Substrate-Competitive, Specific Small-Molecule Inhibitor of PI4KIIα, Inhibits the Growth of Breast Cancer Cells. Cancer Res. 2017 Nov 15;77(22):6253-6266.Products are for research use only. Not for human use.|

Additional information:
Oxysophoridine (Sophoridine N-oxide) is a bioactive alkaloid extracted from the Sophora alopecuroides Linn. Oxysophoridine (Sophoridine N-oxide) shows anti inflammatory, anti oxidative stress and anti apoptosis effects.|Product information|CAS Number: 54809-74-4|Molecular Weight: 264.36|Formula: C15H24N2O2|Chemical Name: (1R,2R,9R,17S)-6-oxo-7,13-diazatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadecan-13-ium-13-olate|Smiles: [O-][N+]12CCC[C@@H]3CN4[C@H](CCCC4=O)[C@@H](CCC1)[C@@H]23|InChiKey: XVPBINOPNYFXID-ACTGZQEFSA-N|InChi: InChI=1S/C15H24N2O2/c18-14-7-1-6-13-12-5-3-9-17(19)8-2-4-11(15(12)17)10-16(13)14/h11-13,15H,1-10H2/t11-,12-,13-,15+,17?/m1/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 33.33 mg/mL (126.08 mM; Need ultrasonic). H2O : 125 mg/mL (472.84 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|Products are for research use only. Not for human use.|

Additional information:
Product information|CAS Number: 1794937-18-0|Molecular Weight: 278.71|Formula: C13H10ClN3O2|Chemical Name: 2-{[6-chloro-3-(²H₃)methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl]methyl}benzonitrile|Smiles: [2H]C([2H])([2H])N1C(=O)N(CC2=CC=CC=C2C#N)C(Cl)=CC1=O|InChiKey: BVUJISIVAHYNLI-FIBGUPNXSA-N|InChi: InChI=1S/C13H10ClN3O2/c1-16-12(18)6-11(14)17(13(16)19)8-10-5-3-2-4-9(10)7-15/h2-6H,8H2,1H3/i1D3|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|Products are for research use only. Not for human use.|

Additional information:
1-Acetyl-3-o-toluyl-5-fluorouracil is a potent an antineoplastic agent.|Product information|CAS Number: 71861-76-2|Molecular Weight: 290.25|Formula: C14H11FN2O4|Chemical Name: 1-acetyl-5-fluoro-3-(2-methylbenzoyl)-1,2,3,4-tetrahydropyrimidine-2,4-dione|Smiles: CC(=O)N1C=C(F)C(=O)N(C(=O)C2=CC=CC=C2C)C1=O|InChiKey: DRXHAKVGNKHFMB-UHFFFAOYSA-N|InChi: InChI=1S/C14H11FN2O4/c1-8-5-3-4-6-10(8)12(19)17-13(20)11(15)7-16(9(2)18)14(17)21/h3-7H,1-2H3|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{D-Cycloserine} site|{D-Cycloserine} Anti-infection|{D-Cycloserine} Protocol|{D-Cycloserine} In stock|{D-Cycloserine} manufacturer|{D-Cycloserine} Epigenetics} |Shelf Life: ≥12 months if stored properly.{{Mirin} MedChemExpress|{Mirin} PI3K/Akt/mTOR|{Mirin} Purity & Documentation|{Mirin} In Vitro|{Mirin} supplier|{Mirin} Autophagy} |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:31985186 |Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vivo:|Oral administration of 1-Acetyl-3-o-toluyl-5-fluorouracil demonstrates a remarkable effect on MH134 solid tumors, the effect being more marked than that of subcutaneous administration of 1-Acetyl-3-o-toluyl-5-fluorouracil. Anti-tumor activity of oral administration of 1-Acetyl-3-o-toluyl-5-fluorouracil at a dose of 0.2 mmol/kg/d is comparable to that of subcutaneous administration of 5-fluorouracil at the same dose. The level of decrease in thymus weight and the magnitude of increase of spleen weight following oral administration of 1-Acetyl-3-o-toluyl-5-fluorouracil at any dose are smaller than those by subcutaneous administration of 5-fluorouracil (0.2 mmol/kg/d).|Products are for research use only. Not for human use.|